Publications by authors named "C C Heuck"
Article Synopsis
- Cytokine release syndrome, often linked to T-cell therapies like talquetamab, causes an increase in interleukin-6 (IL-6), which might inhibit certain liver enzymes (cytochrome P450).
- The study aimed to assess how elevated IL-6 affects the metabolism of other drugs by looking at both standard and extreme IL-6 levels after talquetamab treatment.
- Results showed that while normal IL-6 levels had no significant impact on drug interactions, elevated IL-6 could moderately affect specific liver enzymes, with potential effects peaking 7 to 9 days after the start of treatment.
Article Synopsis
- Talquetamab is the first bispecific antibody targeting GPRC5D, approved for treating relapsed/refractory multiple myeloma in patients who have undergone multiple therapies.
- A matching-adjusted indirect comparison study was conducted to assess its effectiveness compared to selinexor-dexamethasone (sel-dex) and belantamab mafodotin (belamaf).
- Results showed talquetamab provided better overall response rates, complete response rates, and duration of response compared to both sel-dex and belamaf, positioning it as a superior treatment option for patients with triple-class exposed multiple myeloma.
Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab.
Clin Lymphoma Myeloma Leuk
October 2024
Article Synopsis
- Talquetamab is a bispecific antibody that targets the GPRC5D antigen in patients with relapsed/refractory multiple myeloma, showing over 71% overall response rates in clinical trials.
- Adverse events (AEs) associated with talquetamab mainly included dermatologic and oral issues, although the majority were low grade and manageable through various treatment strategies.
- Effective management of more serious AEs, like cytokine release syndrome and neurotoxicity, along with proper education for healthcare providers, can help maintain the quality of life for patients undergoing treatment.
Estimating progression-free survival (PFS) and overall survival superiority during clinical trials of multiple myeloma (MM) has become increasingly challenging as novel therapeutics have improved patient outcomes. Thus, it is imperative to identify earlier end point surrogates that are predictive of long-term clinical benefit. Minimal residual disease (MRD)-negativity is a common intermediate end point that has shown prognostic value for clinical benefit in MM.
View Article and Find Full Text PDF